{"id":429970,"title":"Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100) - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-02","captureTimestamp":"2026-01-02T03:04:41.205000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-clinical-practices/guidance-documents/guidance-drugs-clinical-trials-human-subjects-gui-0100/document.html","snippet":"Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100) This guidance is being consulted on as part of the proposed clinical trial regulation modernization. To participate, please see Consultation:…","rawSnapshotUrl":"/api/snapshots/raw/429970","browseUrl":"https://replay.healtharchive.ca/job-6/20260102030441/https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-clinical-practices/guidance-documents/guidance-drugs-clinical-trials-human-subjects-gui-0100/document.html#ha_snapshot=429970","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}